Om

Research Alliance Corporation III is a special purpose acquisition company formed in 2026 and headquartered in New York, New York. The company operates as a blank check entity, established to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more operating businesses. Research Alliance Corporation III primarily targets opportunities in healthcare and healthcare-related industries, with a particular emphasis on drug development, health technology, diagnostics, and healthcare services. Its structure allows institutional and individual investors to gain exposure to a private operating company that may ultimately combine with the SPAC. The sponsor and management team draw on experience in life sciences investing and analysis to identify and evaluate potential targets. In the broader financial market, Research Alliance Corporation III serves as an intermediary vehicle, channeling capital from public investors to privately held healthcare and health-tech companies seeking access to public markets and additional funding via a business combination transaction.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I RESEARCH ALLIANCE CORP III MED ENDAVU: Køb Research Alliance Corp III ($RACC) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Research Alliance Corp III, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.